Nitric oxide production is increased during murine vaccinia virus infection, but may not be essential for virus clearance. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Nitric oxide production is increased during murine vaccinia virus infection, but may not be essential for virus clearance.

Virology. 1996 Mar 15;217(2):470-7. Unique Identifier : AIDSLINE MED/96183369
Rolph MS; Ramshaw IA; Rockett KA; Ruby J; Cowden WB; Division of Cell Biology, John Curtin School of Medical Research,; Canberra, Australia.

Abstract: Recent reports have highlighted a potential antiviral activity for nitric oxide (NO). The purpose of this study was to investigate the production of NO in mice during vaccinia virus (VV) or herpes simplex virus type 1 infection, and to assess the role of NO in clearance of VV. Reactive nitrogen intermediates (RNI; NO and its stable oxidation products, nitrite and nitrate) were significantly elevated in the plasma of mice infected with these viruses. Furthermore, spleen cells from virus-infected mice produced elevated RNI levels following stimulation in vitro with LPS. NO production during VV infection was critically dependent on the cytokines tumor necrosis factor and interferon-gamma, and on the presence of both CD4+ and CD8+ T lymphocytes. Treatment of VV-infected mice with the nitric oxide synthase inhibitor N(G)-methyl-L-arginine did not alter the course of infection, suggesting that NO may not be essential for the clearance of this virus.
Keywords: Animal Cells, Cultured CD4-Positive T-Lymphocytes/IMMUNOLOGY CD8-Positive T-Lymphocytes/IMMUNOLOGY Ectromelia Virus Ectromelia, Infectious/IMMUNOLOGY Female Interferon Type II/PHYSIOLOGY Mice Mice, Inbred CBA Mice, Inbred C57BL Nitric Oxide/*BIOSYNTHESIS Nitric-Oxide Synthase/ANTAGONISTS & INHIB Spleen/CYTOLOGY Support, Non-U.S. Gov't Tumor Necrosis Factor/PHYSIOLOGY Vaccinia/BLOOD/*IMMUNOLOGY Vaccinia Virus JOURNAL ARTICLEKWDanimalcells,culturedcd4-positivet-lymphocytes/immunologycd8-positivet-lymphocytes/immunologyectromeliavirusectromelia,infectious/immunologyfemaleinterferontypeii/physiologymicemice,inbredcbamice,inbredc57blnitricoxide/KWDbiosynthesisnitric-oxidesynthase/antagonists&inhibspleen/cytologysupport,non-uKWDsKWDgov'ttumornecrosisfactor/physiologyvaccinia/blood/KWDimmunologyvacciniavirusjournalarticle
960830
M9681136

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .